COAGULATION ANALYZERS MARKET ANALYSIS

Coagulation Analyzers Market, by Product Type (Analyzers (Clinical Laboratory Analyzers, Point of Care Analyzers) and Consumables (Reagents & Kits, Point-of-care strips), by Test Type (Activated Partial Thromboplastin Time Test, Prothrombin Time Test, D-Dimer Test, Fibrinogen Test and Other Coagulation Tests), by End User (Hospitals, Diagnostic Laboratories, Research Institutes and Others), and by Geography - Global Trends, and Forecast to 2025

Published In : Jan 2018
Code : CMI1255
Pages :150
Formats :
Excel and PDF
Industry : Medical Devices

Coagulation Analyzers MarketSize and Trends

The global coagulation analyzers market was valued at US$ 2,421.96 million in 2016 and is expected to exhibit a CAGR of 9.7% over the forecast period (2017–2025)

Rising prevalence of heart diseases such as atrial fibrillation and blood disorders is expected to augment the market growth

Increasing cases of heart diseases and blood disorders is expected to lead to increasing demand for coagulation analyzers. According to the Centre for Disease Control and Prevention, in 2017, heart arrhythmia such as atrial fibrillation affected 2.7– 6.1 million population in the U.S. and this number is expected to increase with increasing geriatric population. This population is at higher risk for blood clots including those that cause ischemic stroke. So, increasing geriatric population has also escalated demand for coagulation testing that facilitates rapid interventions, which is expected to help in optimizing patient therapy.

Reduction in the size of coagulation analyzers has led to increasing adoption of these in ambulatory surgical centers. This is owing to its small size, which can fit almost anywhere in the operating unit and offers same results in less turnaround time, making it hassle free and feasible for the operators. Easy operating and functionality of these devices have also made it convenient for patients to be used at homes, in order to measure their coagulation status. For instance, in May 2016, Hoffmann-La Roche Ltd. launched CoaguChek INRange system, in countries accepting the CE Mark. This system is a Bluetooth enabled PT/INR home health device that helps healthcare providers and patients to check their coagulation status and monitor Vitamin K Antagonist (VKA) therapy.